News Releases Keyword Search Year None20232022202120202019201820172016 Jun-01-2022 Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) May-26-2022 Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022 May-05-2022 Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results May-02-2022 Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Apr-28-2022 Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results Apr-13-2022 Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma Apr-01-2022 Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Mar-10-2022 Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results Mar-07-2022 Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results Mar-01-2022 Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
